With Biohaven's Nurtec ODT Off And Running, Focus Turns To What Is Next
The oral CGRP inhibitor for migraine generated solid second quarter results as the company expanded to the prevention setting. Several new potential growth drivers are moving through the pipeline.
You may also be interested in...
AstraZeneca is discontinuing a Phase III trial of the long-acting complement inhibitor it gained via its Alexion acquisition in amyotrophic lateral sclerosis because of lack of efficacy in an interim analysis. Interest is now turning to antisense and cell therapy candidates from other companies that are in late-stage development for the condition.
CEO Vlad Coric said the customizable use of Nurtec ODT to stop and prevent migraine attacks is a differentiating factor that will help it go up against big pharma competitors.
After a prior failure in treating anxiety, the company believes the glutamate modulator showed signs of efficacy in obsessive-compulsive disorder that are worth pursuing, including at a higher dose.